Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved..
Diseases affecting the anterior segment of the eye are the primary causes of vision impairment and blindness globally. Drug administration through the topical ocular route is widely accepted because of its user/patient friendliness - ease of administration and convenience. However, it remains a significant challenge to efficiently deliver drugs to the eye through this route because of various structural and physiological constraints that restrict the distribution of therapeutic molecules into the ocular tissues. The bioavailability of topically applied ocular medications such as eye drops is typically less than 5%. Developing novel delivery systems to increase the retention time on the ocular surfaces and permeation through the cornea is one of the approaches adopted to boost the bioavailability of topically administered medications. Drug delivery systems based on nanotechnology such as micelles, nanosuspensions, nanoparticles, nanoemulsions, liposomes, dendrimers, niosomes, cubosomes and nanowafers have been investigated as effective alternatives to conventional ocular delivery systems in treating diseases of the anterior segment of the eye. This review discussed different nanotechnology-based delivery systems that are currently investigated for treating and managing diseases affecting the anterior ocular tissues. We also looked at the challenges in translating these systems into clinical use and the prospects of nanocarriers as a vehicle for the delivery of phytoactive compounds to the anterior segment of the eye.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:354 |
|---|---|
| Enthalten in: |
Journal of controlled release : official journal of the Controlled Release Society - 354(2023) vom: 16. Feb., Seite 465-488 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Onugwu, Adaeze Linda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anterior segment |
|---|
| Anmerkungen: |
Date Completed 28.02.2023 Date Revised 28.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jconrel.2023.01.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351531572 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351531572 | ||
| 003 | DE-627 | ||
| 005 | 20231226051607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jconrel.2023.01.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351531572 | ||
| 035 | |a (NLM)36642250 | ||
| 035 | |a (PII)S0168-3659(23)00019-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Onugwu, Adaeze Linda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2023 | ||
| 500 | |a Date Revised 28.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Diseases affecting the anterior segment of the eye are the primary causes of vision impairment and blindness globally. Drug administration through the topical ocular route is widely accepted because of its user/patient friendliness - ease of administration and convenience. However, it remains a significant challenge to efficiently deliver drugs to the eye through this route because of various structural and physiological constraints that restrict the distribution of therapeutic molecules into the ocular tissues. The bioavailability of topically applied ocular medications such as eye drops is typically less than 5%. Developing novel delivery systems to increase the retention time on the ocular surfaces and permeation through the cornea is one of the approaches adopted to boost the bioavailability of topically administered medications. Drug delivery systems based on nanotechnology such as micelles, nanosuspensions, nanoparticles, nanoemulsions, liposomes, dendrimers, niosomes, cubosomes and nanowafers have been investigated as effective alternatives to conventional ocular delivery systems in treating diseases of the anterior segment of the eye. This review discussed different nanotechnology-based delivery systems that are currently investigated for treating and managing diseases affecting the anterior ocular tissues. We also looked at the challenges in translating these systems into clinical use and the prospects of nanocarriers as a vehicle for the delivery of phytoactive compounds to the anterior segment of the eye | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Anterior segment | |
| 650 | 4 | |a Drug delivery systems | |
| 650 | 4 | |a Mucoadhesion | |
| 650 | 4 | |a Nanotechnology | |
| 650 | 4 | |a Ocular barriers | |
| 650 | 4 | |a Ocular diseases | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 700 | 1 | |a Nwagwu, Chinekwu Sherridan |e verfasserin |4 aut | |
| 700 | 1 | |a Onugwu, Obinna Sabastine |e verfasserin |4 aut | |
| 700 | 1 | |a Echezona, Adaeze Chidiebere |e verfasserin |4 aut | |
| 700 | 1 | |a Agbo, Chinazom Precious |e verfasserin |4 aut | |
| 700 | 1 | |a Ihim, Stella Amarachi |e verfasserin |4 aut | |
| 700 | 1 | |a Emeh, Prosper |e verfasserin |4 aut | |
| 700 | 1 | |a Nnamani, Petra Obioma |e verfasserin |4 aut | |
| 700 | 1 | |a Attama, Anthony Amaechi |e verfasserin |4 aut | |
| 700 | 1 | |a Khutoryanskiy, Vitaliy V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of controlled release : official journal of the Controlled Release Society |d 1996 |g 354(2023) vom: 16. Feb., Seite 465-488 |w (DE-627)NLM085820296 |x 1873-4995 |7 nnns |
| 773 | 1 | 8 | |g volume:354 |g year:2023 |g day:16 |g month:02 |g pages:465-488 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jconrel.2023.01.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 354 |j 2023 |b 16 |c 02 |h 465-488 | ||